Impact of leuprolide acetate on luteal phase function in women undergoing controlled ovarian hyperstimulation and intrauterine insemination

Deirdre A Duffy, D DUFFY, Deborah L. Manzi, Deborah Manzi, Claudio Benadiva, Donald Maier, Melinda Saunders, John Nulsen
Fertility and sterility · 2006 · vol. 85(2) , pp. 407–411 · doi:10.1016/j.fertnstert.2005.07.1330 · PMID:16595219 · W2024802472
RCT OA: bronze CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This paper investigated the effects of leuprolide acetate on luteal phase function in women undergoing controlled ovarian hyperstimulation and intrauterine insemination.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To determine if the combination of leuprolide acetate (LA) and human menopausal gonadotropin (hMG) results in luteal phase dysfunction. DESIGN: A prospective, randomized clinical trial. SETTING: A tertiary care university fertility center. PATIENT(S): One hundred thirty-five couples with various etiologies of infertility. INTERVENTION(S): Patients were prospectively randomized to receive either hMG and intrauterine insemination (IUI) or luteal phase down-regulation with LA, hMG, and IUI. MAIN OUTCOME MEASURE(S): Serum luteal phase progesterone (P) and luteal phase estradiol (E2) were obtained 9 days after hCG administration. Twenty-four-hour urinary P and luteinizing hormone (LH) were analyzed 9 days after human chorionic gonadotropin (hCG). Endometrial biopsies were performed 11 days after hCG and evaluated for luteal phase defects (LPD) using Noyes' criteria. RESULT(S): No significant differences in the incidence of LPD (11.9% vs. 13.9%), cycle fecundity (16.6% vs. 16.3%), or luteal phase hormone profiles were observed between the groups receiving and not receiving LA. A significant difference in E2 levels (on the day of hCG administration) between cycles with a luteal phase defect (967 pg/mL +/- 106) and without a luteal phase defect (1,422 pg/mL +/- 83) was observed (P<.05). CONCLUSION(S): Pituitary down-regulation with LA combined with hMG did not result in luteal phase dysfunction. The E2 levels on the day of hCG administration in both groups were lower in women with documented luteal phase defects.

My notes (saved in your browser only)

MeSH descriptors

Fertility Agents, Female Infertility, Female Infertility, Female Insemination, Artificial, Homologous Leuprolide Luteal Phase Ovulation Induction Adult Estradiol Estradiol Female Fertility Agents, Female Humans Infertility, Female Infertility, Female Leuprolide Luteal Phase Male Menotropins Menotropins

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (40)

Source provenance

openalex
last seen: 2026-05-13T20:07:10.637958+00:00
pubmed
last seen: 2026-10-08T21:03:44.483075+00:00
License: CC0 · commercial use OK